Moderna Therapeutics LLC has become one of the biopharmaceutical industry’s biggest unicorns – attracting billions of dollars in venture, partnership and grant funding – while revealing few details about its messenger RNA (mRNA) therapeutic platform. But the normally secretive company subjected its pipeline to public scrutiny during an appearance at the J.P. Morgan Healthcare Conference.
Scrip spoke with Moderna CEO Stephane Bancel about before and after the standing-room-only Jan. 9 J.P. Morgan presentation, which was followed by a Jan. 10 news article citing former employees who suggested safety problems for the mRNA technology
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?